Searchable abstracts of presentations at key conferences in endocrinology

ea0081p173 | Pituitary and Neuroendocrinology | ECE2022

The immune microenvironment landscape in pituitary tumors, genes and cells

Vela Patino Sandra , Isabel Salazar Ma. , Remba-Shapiroa Ilan , Pena-Martinez Eduardo , Silva-Roman Gloria , Andoneui-Elguera Sergio , Taniguchi-Ponciano Keiko , Bonifaz Laura , Aguilar-Flores Cristina , Mercado Moises , Marrero-Rodriguez Daniel

The tumor immune microenvironment is essential, it could influence a favorable or negative response against the tumor cells, and it has been related to therapy response and prognostic factors. Tumor infiltrating lymphocytes (TILs) plays an important role in the development, progression, and tumor control, thus presence of TILs could be related to disease-specific traits. The aim of the present work is to evaluate the expression of immune-related genes in forty-two pituitary ad...

ea0081p123 | Endocrine-Related Cancer | ECE2022

The transcriptomic and methylomic landscape of POU1F1 pituitary tumors

Silva Roman Gloria Elena , Salazar Ma Isabel , Taniguchi Ponciano Keiko , Pena Martinez Juan Eduardo , Vela Patino Sandra , Andonegui Elguera Sergio , Gomez Apo Erick , Macias Laura Chavez , Espinosa Cardenas Etual , Ramirez Renteria Claudia , Ferreira Hermosillo Aldo , Sosa Ernesto , Mercado Moises , Marrero-Rodriguez Daniel

Pituitary adenomas (PA) are primarily benign lesions with monoclonal origins from the adenohypophyseal cells and represent 10-15% of all intracranial tumors. Tumors derived from POU1F1 cell lineage are GH-, TSH-, and PRL-secreting tumors that cause important syndromes such as acromegaly, hyperthyroidism, and sexual dysfunction, respectively. Surgical resection is the first line of treatment; the secondary treatment is pharmacological; despite having targets pharmacological in ...